



Atty Dkt. No.: UCAL222
USSN: 10/017,718
Exhibit 1

EXPRESS MAIL NO. EV576489826US		
<p>DECLARATION OF KARL WEISGRABER UNDER 37 C.F.R. § 1.132</p> <p>Address to: Commissioner for Patents Alexandria, VA 22313-1450</p>	Attorney Docket Confirmation No.	UCAL-222 5282
	First Named Inventor	Karl H. Weisgraber
	Application Number	10/017,718
	Filing Date	December 14, 2001
	Group Art Unit	1632
	Examiner Name	T.N. Ton
	Title	<i>Gene-targeted animal model of apolipoprotein E4 domain interaction and uses thereof</i>

Considered
5.9.05
TNT

Dear Sir:

1. I, Karl Weisgraber, declare and say I am a co-inventor of the claims of the above-identified patent application.

2. I have read the Office Action dated October 1, 2004 in this application and understand that the Examiner would like to see further evidence that a gene-targeted mouse that produces an Arg-61 modified apoE exhibits a phenomenon associated with Alzheimer's Disease (AD).

3. The following paragraphs describe experiments conducted in my laboratory. The results of the experiments provide further evidence for the fact that a gene-targeted mouse that bears a Thr→Arg substitution at a position equivalent to Arg-61 in human apoE4 exhibits a phenomenon associated with AD, and therefore is suitable for use in identifying agents that reduce a phenomenon associated with AD.